141 related articles for article (PubMed ID: 12659837)
1. On the same cell type GPI-anchored normal cellular prion and DAF protein exhibit different biological properties.
Li R; Liu T; Yoshihiro F; Tary-Lehmann M; Obrenovich M; Kuekrek H; Kang SC; Pan T; Wong BS; Medof ME; Sy MS
Biochem Biophys Res Commun; 2003 Apr; 303(2):446-51. PubMed ID: 12659837
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
[TBL] [Abstract][Full Text] [Related]
3. Discordant and heterogeneous expression of GPI-anchored membrane proteins on leukemic cells in a patient with paroxysmal nocturnal hemoglobinuria.
Shichishima T; Terasawa T; Hashimoto C; Ohto H; Takahashi M; Shibata A; Maruyama Y
Blood; 1993 Apr; 81(7):1855-62. PubMed ID: 7681703
[TBL] [Abstract][Full Text] [Related]
4. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses.
Bergelson JM; Chan M; Solomon KR; St John NF; Lin H; Finberg RW
Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6245-8. PubMed ID: 7517044
[TBL] [Abstract][Full Text] [Related]
5. Effect of glycosylphosphatidylinositol anchor-dependent and -independent prion protein association with model raft membranes on conversion to the protease-resistant isoform.
Baron GS; Caughey B
J Biol Chem; 2003 Apr; 278(17):14883-92. PubMed ID: 12594216
[TBL] [Abstract][Full Text] [Related]
6. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
7. Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accelerating factor protein in cells.
Walter EI; Ratnoff WD; Long KE; Kazura JW; Medof ME
J Biol Chem; 1992 Jan; 267(2):1245-52. PubMed ID: 1370460
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of GPI-anchored proteins from the plasma membrane activates apical endocytosis in pancreatic acinar cells.
Freedman SD; Kern HF; Scheele GA
Eur J Cell Biol; 1998 Feb; 75(2):163-73. PubMed ID: 9548373
[TBL] [Abstract][Full Text] [Related]
9. PI-specific phospholipase C cleavage of a reconstituted GPI-anchored protein: modulation by the lipid bilayer.
Lehto MT; Sharom FJ
Biochemistry; 2002 Jan; 41(4):1398-408. PubMed ID: 11802743
[TBL] [Abstract][Full Text] [Related]
10. Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.
Ratnoff WD; Knez JJ; Prince GM; Okada H; Lachmann PJ; Medof ME
Clin Exp Immunol; 1992 Mar; 87(3):415-21. PubMed ID: 1371955
[TBL] [Abstract][Full Text] [Related]
11. Glycosylphosphatidylinositol Anchor Modification Machinery Deficiency Is Responsible for the Formation of Pro-Prion Protein (PrP) in BxPC-3 Protein and Increases Cancer Cell Motility.
Yang L; Gao Z; Hu L; Wu G; Yang X; Zhang L; Zhu Y; Wong BS; Xin W; Sy MS; Li C
J Biol Chem; 2016 Feb; 291(8):3905-17. PubMed ID: 26683373
[TBL] [Abstract][Full Text] [Related]
12. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
[TBL] [Abstract][Full Text] [Related]
13. An internally positioned signal can direct attachment of a glycophospholipid membrane anchor.
Caras IW
J Cell Biol; 1991 Apr; 113(1):77-85. PubMed ID: 1706725
[TBL] [Abstract][Full Text] [Related]
14. Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55).
Kuraya M; Fujita T
Int Immunol; 1998 Apr; 10(4):473-80. PubMed ID: 9620603
[TBL] [Abstract][Full Text] [Related]
15. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes.
Ohta R; Imai M; Fukuoka Y; Miwa T; Okada N; Okada H
Microbiol Immunol; 1999; 43(11):1045-56. PubMed ID: 10609614
[TBL] [Abstract][Full Text] [Related]
16. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C.
Hindmarsh EJ; Marks RM
Eur J Immunol; 1998 Mar; 28(3):1052-62. PubMed ID: 9541601
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage.
Walter EI; Roberts WL; Rosenberry TL; Ratnoff WD; Medof ME
J Immunol; 1990 Feb; 144(3):1030-6. PubMed ID: 1688588
[TBL] [Abstract][Full Text] [Related]
18. Prion protein expression in Chinese hamster ovary cells using a glutamine synthetase selection and amplification system.
Blochberger TC; Cooper C; Peretz D; Tatzelt J; Griffith OH; Baldwin MA; Prusiner SB
Protein Eng; 1997 Dec; 10(12):1465-73. PubMed ID: 9543009
[TBL] [Abstract][Full Text] [Related]
19. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
20. Traffic, polarity, and detergent solubility of a glycosylphosphatidylinositol-anchored protein after LDL-deprivation of MDCK cells.
Hannan LA; Edidin M
J Cell Biol; 1996 Jun; 133(6):1265-76. PubMed ID: 8682863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
